Literature DB >> 8756828

Diffuse panbronchiolitis in the United States.

J E Fitzgerald1, T E King, D A Lynch, R M Tuder, M I Schwarz.   

Abstract

Diffuse panbronchiolitis (DPB), an important cause of progressive obstructive lung disease in the Far East, represents a distinctive sinobronchial syndrome with typical radiologic and histologic features. We have identified DPB in five citizens of the United States, three with histologic confirmation, who have never traveled to the Far East. There were four men and one woman, whose ages ranged from 46 to 75 yr at the time of diagnosis. All had a prior history of chronic sinusitis and presented with cough, dyspnea, and sputum production. Three were never smokers and two were current smokers. Pulmonary function testing revealed severe airflow limitation (the FEV1 ranging from 22% to 56% of predicted), and overdistention. All patients had high-resolution computed tomographic (HRCT) scans indicating centrilobular nodules with adjoining thickened and dilated bronchioles. In the three patients in whom open lung biopsy was performed, there was bronchiolocentric infiltration of lymphocytes, plasma cells, and foamy macrophages. Three patients remain alive and are being treated with chronic macrolide therapy. The clinical, radiographic, and histologic features of these patients closely resemble those described in Japanese patients. DPB must be considered in the differential diagnosis of sinopulmonary syndromes, bronchiolitis, and cryptic cases of obstructive lung disease among United States citizens, since therapy now offers an improved prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 8756828     DOI: 10.1164/ajrccm.154.2.8756828

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

1.  Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis.

Authors:  H Satoh; H Ishikawa; Y T Yamashita; M Ohtsuka; K Sekizawa
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

Review 2.  Erythromycin and diffuse panbronchiolitis.

Authors:  H Koyama; D M Geddes
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

3.  Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells.

Authors:  Y Aoki; P N Kao
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis.

Authors:  Masaaki Sumi; Hiroaki Satoh; Katsunori Kagohashi; Hiroichi Ishikawa; Kiyohisa Sekizawa
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 5.  Macrolides for diffuse panbronchiolitis.

Authors:  Xiufang Lin; Jing Lu; Ming Yang; Bi Rong Dong; Hong Mei Wu
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

Review 6.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

7.  Clinical profiles of Chinese patients with diffuse panbronchiolitis.

Authors:  K W Tsang; C G Ooi; M S Ip; W K Lam; H Ngan; E Y Chan; B Hawkins; C S Ho; R Amitani; E Tanaka; H Itoh
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

8.  The Usefulness of a Transbronchial Lung Cryobiopsy for Diffuse Bronchiolitis.

Authors:  Hideaki Yamakawa; Tamiko Takemura; Shintaro Sato; Tomohiko Nakamura; Tomotaka Nishizawa; Tomohiro Oba; Rie Kawabe; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hidekazu Matsushima
Journal:  Intern Med       Date:  2020-12-07       Impact factor: 1.271

9.  Diffuse panbronchiolitis: not just an Asian disease: Australian case series and review of the literature.

Authors:  Mp Anthony; S Singham; B Soans; G Tyler
Journal:  Biomed Imaging Interv J       Date:  2009-10-01

10.  Diffuse panbronchiolitis, a potentially misdiagnosed sinopulmonary syndrome.

Authors:  Atilla G Atici; Serhat Findik; Bilal Sengul; Levent Yildiz; Oguz Uzun; Levent Erkan
Journal:  Ann Saudi Med       Date:  2005 Nov-Dec       Impact factor: 1.526

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.